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1. Introduction 
 
The concept of ventilator induced lung injury (VILI) has been described more than 20 
years ago (1,2). Lung injury can be the consequence of volotrauma when too high 
tidal volumes are delivered, to barotrauma when airway pressures are too high or to 
atelectrauma when some lungs area alternate between collapse and opening at 
every breath. Protective ventilation with low tidal volumes (VT) indexed to predicted 
body weight (PBW), moderately high plateau pressure and relatively high positive 
end-expiratory pressure (PEEP) has been recognized as effective in improving 
outcomes in patients suffering from acute respiratory distress syndrome (ARDS) (3).  
The interest of delivering protective ventilation in other patients at risk for developing 
VILI has not been extensively described. Because transplanted lungs are exposed to 
cold ischemia after the retrieval process and then to ischemia-reperfusion injuries, 
they are probably particularly at risk for developing VILI. Protective ventilation 
strategies in the post-operative period should thus be of particular interest in lung 
transplanted patients. The effect of using such strategies after lung transplantation 
has however not been extensively described. In addition, there is some evidence that 
ventilation delivered in the post-operative period after lung transplantation is very 
heterogeneous and sometimes not very protective (4).  
Primary graft dysfunction (PGD) is one of the most important cause of mortality and 
morbidity during the early post-transplantation period (0 to 30 days). In addition , 
PGD is correlated with an increased risk of developing a bronchiolitis obliterans 
syndrome, which is going to impact long term survival and quality of life (5).PGD 
usually occurs within the first 72 hours post-transplantation and affects nearly 30% of 
the transplanted patients (5). It is considered as the result of cold ischemia and 
reperfusion mechanisms resulting in pulmonary oedema, infiltrates and hypoxemia 
but could also be enhanced by non-protective ventilation (5, 6). 
As according to the latest data of the International Society of Heart and Lung 
Transplantation (ISHLT), lung transplantation is widely performed around the world 
(7), the question of optimizing ventilatory support after lung transplantation is of major 
interest. In addition, it is important to be aware that even if the interest of applying 
lung protective ventilation strategies has been extensively described, recent studies 
have shown that the protective ventilation guidelines are often not optimally applied 
both in ARDS and in post-transplant patients (4, 8). 
The main objective of this study was to analyse how mechanical ventilation was 
applied to the lung transplanted patients during their ICU stay in the Lausanne 
University Hospital ICU and to determine whether there were differences in the 
ventilation applied according to the lung disease that led to transplantation. 
The second objective of this study was to assess whether the ventilation modalities 
applied in the post-operative period could be associated with lung transplant patients’ 
outcomes, in particular with the ventilation duration and the ICU length of stay. 
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2. Methods 
 
This study was a retrospective analysis. It took place in the Adult Intensive Care Unit 
(ICU) of the Lausanne University hospital (CHUV). Data were collected during the 
16th of July 2014 to the 31st of October 2017 period.  
2.1 Ethics committee  
The study protocol was accepted by the Commission cantonale d'éthique de la 
recherche sur l'être humain (CER-VD) (protocole reference number 2017-01181). A 
waiver of consent was obtained for this retrospective study. 
2.2 Inclusion/exclusion criteria  
All the patients hospitalized during the study period in the ICU after bilateral lung 
transplantation were screened for inclusion in the study except if they had previously 
explicitly mentioned that they did not want to participate in a research project.  
All the patients screened were included except if they had one of the following non-
inclusion criterion: unilateral lung transplantation, concomitant transplantation of 
another organ, second lung transplantation or transplantation of lungs preconditioned 
using the ex vivo lung perfusion technique. 
2.3 Data collection 
Data were collected from the patients’ medical file (Soarian and Archimede) and 
monitoring system (Metavision). The data were collected using an excel file. To 
minimise the risk of errors, we specified data limits for each excel file cell. The data 
collected are listed hereafter. 
2.3.1 Patients characteristics and general data  
Demographic and general patients’ data were collected: age at the time of 
transplantation, sex, weight, height, reason for transplantation, whether or not the 
patient was on the emergency transplantation list (including the reason) and 
comorbidities (in particular past history of coronary or renal disease or diabetes). 
Predicted body weight (PBW) was calculated based on the patient’s sex and height 
(9). 
The dates of ICU admission and discharge, the date of hospital discharge, the 
destination after the hospital stay, the Simplified Acute Physiology Score (SAPS) II at 
ICU admission and the sequential organ failure assessment (SOFA) scores (10) at 
day 1 and 3 after transplantation were also recorded. In case of death in the ICU or 
during the hospital stay, the date and reason of death was also recorded. 
The pulmonary graft dysfunction (PGD) score was computed at day 1 and 3. This 
score is a tool to determine the severity of acute lung injury after lung transplantation. 
Based on the presence/absence of pulmonary oedema on chest radiography and on 
ratio of arterial fraction of oxygen/fraction of inspired oxygen, (Pa02/Fi02), points are 
attributed from a total of 0 to 3 (11).  
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2.3.2 Invasive mechanical ventilation data.  
The following general ventilation related data were collected during the ICU stay: 
interface for ventilation, date of extubation, total duration of mechanical ventilation, 
need for reintubation and need for tracheostomy.  
In addition to these general ventilation data, the following parameters were collected 
every 6 hours from admission in the ICU to the 72sd hour of ICU stay and then every 
24h (censured at 60 days): 
- Pulse oximetry, ventilation mode (volume controlled –VC-, pressure controlled 
–PC- or pressure support –PS-), inspired oxygen fraction 
- Ventilator settings (according to the ventilation mode): set respiratory rate, 
inspiration/expiration ratio, set tidal volume or inspiratory pressure, set positive 
end expiratory pressure -PEEP- 
- Monitored parameters (according to the ventilation mode): respiratory rate, 
tidal volume, peak pressure, plateau pressure, driving pressure for VC 
computed as plateau pressure – PEEP.  
2.3.3 Non-invasive ventilatory support data 
The following data were collected every 6 hours from admission in the ICU to the 
72sd hour of ICU stay and then every 24h (censured at 60 days): 
- Use of non-invasive ventilation (NIV), total number of NIV sessions and total 
time spent under NIV, set inspiratory positive airway pressure (IPAP) and set 
PEEP. 
- Use of high flow oxygen therapy, time in hours spent under high flow oxygen 
therapy, gaz flow and FIO2 during high flow oxygen therapy 
2.4 Data analysis  
Descriptive statistics were performed in the global study population and in four 
subgroups separated according to the reason for transplantation (cystic fibrosis –CF-, 
chronic obstructive pulmonary disease –COPD-, interstitial lung disease –ILD- and 
other diseases). The normality of the data distribution was tested with the D'Agostino-
Pearson test. As a majority of the variable had a non-normal distribution, the results 
are provided as median [IQR]. Comparisons between the subgroups were performed 
for continuous data according to the data distribution using one way ANOVA and 
multiple T-Tests with Dunn's correction for post-hoc pairwise comparisons or with the 
corresponding ANOVA on rank. Proportions were compared using a chi2 or Fisher 
exact test as appropriate. 
To test the effect of non-protective ventilation with high VT, the patients were split in 
the two following groups: non-protective VT group when delivered VT were above 
8ml/kg PBW during more than 25% of time and protective VT group when delivered 
VT were lower than 8ml/kg PBW during more than 75% of time. Patients’ 
characteristics and outcomes were compared between the two groups using T-test or 
Mann-Whitney tests according to the data distribution. 
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To test the effect of non-protective ventilation with high driving pressures (DP), 
defined as plateau pressure - PEEP, the patients ventilated in volume assist control 
(VAC) were split in the two following groups: non-protective DP group when DP was 
higher than 15 cmH2O during more than 25% of time and protective DP group when 
DP was lower than 15 cmH2O during more than 75% of time. Patients’ characteristics 
and outcomes were compared between the two groups using T-test or Mann-Whitney 
tests according to the data distribution. 
3. Results 
 
3.1 Patients characteristics  
Sixty-seven patients received lung transplant in the Lausanne University Hospital 
during the 16.07.2014 to 31.10.2017 period. Seven patients were excluded from the 
present analysis, one because of unavailability of his medical record and 6 because 
they had one of the predefined exclusion criterion (second lung transplant or 
concomitant transplant of another organ). No unilateral lung transplants were 
performed during the study period. 
Sixty patients were consequently included in the present analysis. The main reason 
for transplantation was cystic fibrosis (16/60 patients; 27%) followed by chronic 
obstructive lung disease (COPD) (15/60 patients; 25%), interstitial lung disease (ILD) 
(15/60 patient; 25%) and other diseases (14/60; 23%). Details are shown in Figure 1. 
 
 
 
 
Figure 1 : Reasons for transplantation by disease category and number of patients with the disease (n(%)). 
CF = cystic fibrosis ; COPD = chronic obstructive pulmonary disease ; IPF = idiopathic pulmonary fibrosis ; PF = 
pulmonary fibrosis ; CTD = connective tissue disease ; LALM = leiangioleiomyomatosis ; GVHD = graft versus host 
disease ; PAHT = pulmonary arterial hypertension ; α1 ATD = α1 antitrypsin deficiency 
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Among the 60 patients included, 6 of them were transplanted in emergency. The 
reasons for emergency were intubation because of acute respiratory failure (4/6 
(66%)) and severe pulmonary arterial hypertension related hemodynamic instability 
(2/6 (33%)). The repartition of the patients transplanted in emergency according to 
the reason for transplantation is mentioned in Figure 2. 
 
 
 
 
 
Among the 60 included patients, twenty-nine of them were males (48%) and 31 
females (52%). At the time of transplantation, median age was 48.0 years [32.8-
59.0], median height was 168 cm [159-174], median weight was 60 kg [52-71], and 
median BMI was 22.2 kg/m2 [19.1-24.4]. The highest BMI value was 33.3 
kg/m2.Concerning the comorbidities at the time of transplantation, only two patients 
were known for chronic coronary disease (3%) and 6 suffered from diabetes (6%). 
No patient was known for chronic renal failure.  
General patients’ characteristics for the subgroups of patients according to the 
reason for transplantation are given in Table 1. 
 
General 
characteristics 
CF COPD ILD 
Other 
reason for 
transplanta
tion 
All 
ANOVA
s 
Age (y) 28±10 b) c) 59±5 a)d) 52±11 a), 43±12b) 46±14 <0.0001 
Height (cm) 167±10 165±8 170±10 165±9 167±9 Ns 
Weight (kg) 54.3±11.8 c) 61.6±11.1 73.4±15 a) 62.7±15.5 63 ± 15.0 <0.0001 
Predicted body 
weight  
61±11.2 59.1±8.9 63.9±11 58.1±10.2 61 ±10 Ns 
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Figure 2 : Patients transplanted in emergency according to the reason 
for transplantation. Numbers and percentages. 
CF = cystic fibrosis COPD = chronic obstructive lung disease ILD = 
interstitial lung disease  Tx = transplantation 
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Men 8 (50%) 7 (47%) 9 (60%) 5 (36%) 29 (48%) Ns 
Women 8 (50%) 8 (53%) 6 (40%) 9 (64%) 31 (52%) Ns  
Coronary 
arteries disease 
0 2 (13%) 0 0 2 (3%) Ns 
Chronic renal 
disease 
0 0 0 0 0 Ns 
Diabetes 6 (37%) 0 0 0 6 (10%) Ns 
Table 1 : General characteristics according to the reason for transplantation and for all the 
patients (n=60). a) p-value < 0.05 compared to CF, b) p-value < 0.05 compared to COPD, c) p-
value < 0.05 compared to ILD ,d) p-value < 0.05 compared to Other 
CF = cystic fibrosis COPD = chronic obstructive lung disease ILD = interstitial lung disease Other = 
other patients 
 
3.2 Gravity scores 
Overall, SAPS II score at admission was 32 [27-37] corresponding to a predicted 
mortality of 14.7 % [7.9-23.6]. SOFA score at day 1 was 5 [4-7]. PGD scores at day 1 
and 3 are mentioned in table 2. SAPS II, SOFA score and PGD score for the 
subgroups of patients according to the reason for transplantation are mentioned in 
Table 2 and Figure 3. 
Score CF COPD ILD Other All ANOVAs 
SAPS II 27 [23-35] 34 [30-37] 32 [27.38] 35 [26-43] 32 [27.37] Ns 
SOFA 
day 1 
5 [3-5] c]d] 5 [3.2-7] 7 [5.2-9]a] 8 [5.5-10]a] 5 [4-7] 0.0056 
SOFA 
day 3 
2 [1.5-4] 4 [2-6] 10.5 [4.2-13.7] 5.5 [2.5-10.5] 3.5 [2-7.25] Ns 
PGD 0-1 
day 1 
11/16 9/15 5/15 5/14 30 Ns 
PGD 0-1 
day 3 
12/16 9/15 6/15 10/14 30 Ns 
PGD > 1 
day 1 
5/16 6/15 10/15 9/14 20 Ns 
PGD > 1 
day 3 
4/16 6/15 9/15 4/14 23 Ns 
Table 2 : Gravity Score data according to subgroups of reason for transplantation and for all the 
patients (n=60). a) p-value < 0.05 compared to CF, b) p-value < 0.05 compared to COPD, c) p-value < 
0.05 compared to ILD ,d) p-value < 0.05 compared to Other. 
CF = cystic fibrosis COPD = chronic obstructive lung disease ILD = interstitial lung disease Other = other 
patients. PGD = primary graft dysfunction SOFA : sequential organ failure assessment SAPS = simplified 
acute physiology score 
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3.3 General outcomes 
Overall, the lung transplanted patients stayed in the hospital (including stay in ICU) 
for a median of 18.8 [14.0-29.6] days. They stayed in the ICU for a median of 4.7 
days [3.1-9.6]. General outcome data for the subgroups of patients according to the 
reason for transplantation are given in Table 3.  
Outcomes CF COPD ILD Other  All ANOVAs 
Stay in ICU (days) 
4.5  
[3.7-7.8] 
4.1  
[2.5-7.6] 
8.9  
[4.3-25.9] 
5.3 
[11-17] 
4.7  
[3.1-9.6] 
Ns 
Total stay in hospital 
(days) 
20.5 
[16.5-
27.5] 
17.7 
[13.9-
20.4] 
18.3 
[10.6-
41.9] 
26.9 
[11.8-45] 
18.8 
[14-29.6] 
Ns 
Table 3 : General outcome according to subgroups of reason for transplantation and for all the 
patients (n=60). a) p-value < 0.05 compared to CF, b) p-value < 0.05 compared to COPD, c) p-value < 
0.05 compared to ILD ,d) p-value < 0.05 compared to Other 
CF = cystic fibrosis COPD = chronic obstructive lung disease ILD = interstitial lung disease Other = 
other patients 
 
Two patients died during the hospital stay. These two patients died in the ICU 
respectively 67 days after transplantation in a context of persistent respiratory failure 
with very difficult weaning and 68 days because of refractory septic shock of 
abdominal origin. 
Thirty one patients (52%) were discharged to another hospital (including 
rehabilitation centres). The others 29 (48 %) patients were discharged home.  
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Figure 3 : SOFA score at day 1 post transplantation according to the 
reason for transplantation. 
CF = cystic fibrosis COPD = chronic obstructive lung disease ILD = 
interstitial lung disease Tx = transplantation 
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3.4 Ventilation data  
3.4.1 Interface used, ventilation duration and information related to 
weaning from mechanical ventilation  
All patients were mechanically ventilated through an endotracheal tube at ICU 
admission. Median duration of invasive mechanical ventilation was 1.0 [0.6-3.6] day. 
Extreme durations of invasive mechanical ventilation were 4 hours 7 minutes and 67 
days. Twenty one patients (35%) were mechanically ventilated during more than 48h. 
Ten of them (17% of total) were ventilated during more than 7 days. Overall, 5 over 
60 patients had to be reintubated. The number of reintubated patients per subgroups 
is given in Table 4. 
Mechanical ventilation duration and need for reintubation in the subgroups according 
to the reason for transplantation are illustrated in Figure 4 and Table 4.  
 
 
 
Ventilation 
outcome 
CF group COPD group ILD group Other group All ANOVAs 
Duration of MV  
0.7 c)d) 
[0.4-2.1] 
0.7 c)d) 
[0.5-1.2] 
3.86 a)b) 
[0.81-18.9] 
2.4a)b) 
[0.63-10] 
1  
[0.6-3.6] 
0.0254 
MV more than 48h 4/16 (25%) 1/15 (7%) 8/15 (53%) 7/14 (50%) 
20/60 
(33%) 
0.0237 
MV more than 7 
days 
1/16 (6%) 0/15 6/15 (40%) 3/14 (21%) 
10/60 
(16%) 
0.0158 
Reintubation 1/16 (6%) 1/15 (7%) 3/15 (20%) 0/14 (0%) 
5/60 
(8%) 
Ns 
Table 4 : Ventilation outcome data according to subgroups of reason for transplantation and for all 
the patients (n=60). a) p-value < 0.05 compared to CF, b) p-value < 0.05 compared to COPD, c) p-
value < 0.05 compared to ILD ,d) p-value < 0.05 compared to Other 
CF = cystic fibrosis COPD = chronic obstructive lung disease ILD = interstitial lung disease Other = 
other patients MV = mechanical ventilation 
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Figure 4: Duration of mechanical ventilation in days according 
to the subgroups of main reason for transplantation. 
CF = cystic fibrosis COPD = chronic obstructive lung disease ILD 
= interstitial lung disease. 
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Figure 5 represents the total number of patients under invasive mechanical 
ventilation over time both for all the patients and for the subgroups of patients 
according to the reason for transplantation.  
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Nine patients (15%) were tracheotomized during the ICU stay. One of them suffered 
from CF, 1 from COPD, 4 from ILD and 3 from other disease (p ANOVA >0.05) 
 
3.4.2 Ventilatory modes and ventilator parameters  
For controlled ventilation, volume assist control (VAC) mode was used in 57 (95%) 
patients. Pressure assist control (PAC) was used in 13 (22%) patients. The use of 
these two modes is not mutually exclusive. 
Pressure support ventilation (PSV) was used for weaning in all the patients. In 34 
(57%) patients, PSV was used during more than 6 hours. Total duration spent under 
PSV, computed as the total number of 6-hour periods spent under PSV, was in 
median 1 [0-4] periods. For CF, COPD, ILD and other patients this duration was 
respectively 0 [0-1], 0 [0-2], 6 [1-43], 2.5 [0-4] (p ANOVA = 0.0069, CF group was 
different from ILD group and COPD group was different from ILD group with p-value 
<0.05).  
Detailed set and measured ventilator parameters are given for the global population 
and for the subgroups in Table 5 for all modes, controlled modes, volume assist 
control, pressure assist control and pressure support modes  
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Figure 5 : Number of patients under invasive mechanical ventilation over time for all the patients (a) and according to the reason for 
transplantation (b for CF group, c for COPD group, d for ILD group, e for other patients). 
CF =cystic fibrosis COPD = chronic obstructive lung disease ILD = interstitial lung disease Other = other patients MV = mechanical 
ventilation Tx = transplantation  
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All modes 
Parameter CF COPD ILD Other All ANOVAs 
FI02, all stay 29 [2-35] 
c)d) 29 [24-35.3] c)d) 35 [28-43] b) 31 [28-40] a)b) 35 [30-41] <0.0001 
PEEP during MV 6 [5-8] b) 5 [5-6]a)c) 6 [5-8]b) 6 [5-8] 6[5-8] 0.0193 
All controlled modes 
Set  
parameter 
CF COPD ILD Other All ANOVAs 
Respiratory rate [breath/min] 20 [17-23]c)d) 18 [16-20]c) 15 [14-18]a)b)d) 17 [16-20]a)c) 17 [15-20] <0.0001 
Volume assist control  
Set  
parameters 
CF COPD ILD Other All ANOVAs 
VT [ml] 359 [339-448] 400 [350-445] 400 [310-450] 400 [352-450] 
400 [340-
450] 
Ns 
VT per PBW [ml/kg] 6.0 [5.7-6.6] b) 6.8 [6.5-7.2]a)c)d) 6.1 [5.9-6.9] b) 6.2 [5.8-6.8] b) 
6.2 [5.7-
6.8] 
<0.0001 
PEEP [cmH20] 7.7 [6-8]
b) 5 [5-6]a)c)d) 7 [5-8]b) 6.5 [5-8]b) 7 [5-8] <0.0001 
Measured  
parameters 
CF COPD ILD Other All ANOVAs 
P peak  29 [24-34]b)d) 24 [21-26]a)c)d) 27 [23-31] b) 26 [23.5-29]a)b) 26 [23-31] <0.0001 
P plat   23 [19-28]b) 19 [16-20]a)c)d) 23 [20-26]b) 21 [19.25-25]b) 21 [19-26] <0.0001 
Driving pressure  15 [13-20]b) 13 [11-14]a)c)d) 16 [14-18]b) 15 [14-17]b) 15 [13-18] <0.0001 
Pressure assist control  
Set  
parameter 
CF COPD ILD Other All ANOVAs 
P insp  13 [13-17] 14 [13-15] 17 [16-18] 15[15-20] 16 [13-19] Ns 
Measured  
parameter 
CF COPD ILD Other All ANOVAs 
VT[ [ml] 410 [297-508] 466 [375-517] 388 [308-475] 230 [164-420] 
387 [226-
459] 
0.0217 
Pressure support 
Set  
parameter 
CF COPD ILD Other All ANOVAs 
Pressure support level 10 [8-20] c)d) 8 [7-18]d) 13 [12-24]a)d) 13 [12-22]a)b)c) 13 [10-24] <0.0001 
Measured  
parameter 
CF COPD ILD Other All ANOVAs 
VT [ml] 360 [290-437]b) 
467 [372-
679]a)c)d) 
403 [309-
501]b) 
358 [287-
416]b) 
377 [302-
471] 
0.0002 
Table 5 : Ventilation parameters, sorted by mode of mechanical ventilation for all the patients [n=60] and 
according to the reason for transplantation. a] p-value < 0.05 compared to CF, b] p-value < 0.05 compared 
to COPD, c] p-value < 0.05 compared to ILD ,d] p-value < 0.05 compared to Other. 
CF = cystic fibrosis COPD = chronic obstructive lung disease ILD = interstitial lung disease Other = other 
disease, Fi02 = inspired oxygen fraction, volume PEEP = positive end expiratory pressure, MV = mechanical 
ventilation, VT = tidal volume; PBW =predicted body weight Ppeak = peak pressure, P plat= plateau 
pressure, P insp = inspiratory pressure 
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The major determinants characterising protective ventilation during volume assist 
control ventilation are mentioned in Table 6. 
 
Volume assist control  
Set  
parameters 
CF COPD ILD Other All ANOVAs 
VT < 6ml/kg in % 
0  
[0-3] 
0 
[0-0] 
10  
[0-53] 
0  
[0-5] 
0  
[0-50] 
Ns 
6 < VT <8 ml/kg in % 
2  
[0-2] 
100  
[67-100] 
76 
[45-100] 
100 
[17-100] 
89 
[24-100] 
Ns 
PEEP <8 cmH20 in %  
100  
[85-100] 
100  
[100-100] 
100  
[60-100] 
100  
[83-100] 
100  
[100-100] 
Ns 
PEEP <6 cmH20 in % 
33  
[0-100] 
 
100  
[100-
100]c) 
20  
[0-95]b) 
51  
[0-100] 
100  
[50-100] 
 
0.0271 
Mesured  
parameters 
CF COPD ILD Other All ANOVAs 
P plat  <30  cmH20 in % 100 [100-100] 
100  
[100-100] 
100  
[95-100] 
100  
[100-100] 
100  
[100-100] 
Ns 
P plat  <25  cmH20 in % 100 [84-100] 
100  
[100-
100]c) 
86  
[62-100]b) 
100  
[94-100] 
100  
[86-100] 
0.0183 
P plat  <20  cmH20 in % 45 [0-92] 
100 [63-
100] 
38 [0-58] 53 [25-100] 56 [21-100] Ns 
Driving pressure <15 
cmH20 in % 
100 [65.9-
100] 
100 [83-
100] 
50 [33-
100] 
64.70 [46-
100] 
83.76 [49-
100] 
Ns 
Table 6 : Determinants of protective ventilation in volume assist control for all the patients (n=60) and 
according to the reason for transplantation. Total percentages of recorded values. a) p-value < 0.05 
compared to CF, b) p-value < 0.05 compared to COPD, c) p-value < 0.05 compared to ILD ,d) p-value < 
0.05 compared to Other. 
CF = cystic fibrosis COPD = chronic obstructive lung disease ILD = interstitial lung disease Other = other 
disease; VT = tidal volume PEEP = positive end expiratory pressure; Pplat =  Plateau pressure 
 
3.4.3 Non-invasive ventilatory support 
Among the 60 patients and during their ICU stay, 39 received non-invasive ventilation 
(65%), for a median number of sessions of 9 [5-12] and for a median duration of 6.9 
hours [3.1-10]. Median inspiratory positive airway pressure (IPAP) was set at 13 [10-
24] cmH20 and median PEEP at 7 cmH2O [6-8].  
High flow oxygen therapy was used for 8 patients (13%) for a median of 37.1 [11.6-
99.7] hours and with a median gas flow of 35 [32.5-47.5] l/min.  
Data sorted by patients’ subgroups are displayed in Table 7. 
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NIV Parameter CF COPD ILD Other All 
ANOVA
s 
NIV Number of 
sessions 
2.5 [0-7.3] 5 [0-10.5] 9 [1.5-16.5] 1 [0-6.8] 
9 [5-12] Ns 
NIV Hours under NIV 3.2 [0-7.7] 3.7 [0-7.9] 6.5 [0.4-9.6] 1.1 [0-5.7] 6.9 [31-10] Ns 
NIV IPAP  12 [10-13] 13 [11-15] 13 [12-15] 12 [10.75-14] 13 [11-14] Ns 
NIV PEEP 7 [5-7]c) 7 [6-7.5]c) 7 [7-8]a)b) 7 [6-7] 7 [6-8] 0.0012 
HFOT Oxygen flow HD No values  30 [30-32.5] No values  No values 35 [32. -47.5] - 
Table 7: non-invasive ventilator support results according to subgroups of reason for transplantation and for all 
the patients (n=60). a) p-value < 0.05 compared to CF, b) p-value < 0.05 compared to COPD, c) p-value < 0.05 
compared to ILD ,d) p-value < 0.05 compared to Other. 
CF = cystic fibrosis COPD = chronic obstructive lung disease ILD = interstitial lung disease Other = other patients 
NIV = non-invasive ventilation HFOT = high flow oxygen therapy IPAP = inspiratory positive airway pressure 
 
3.5 Patients characteristics and outcomes according to the predefined 
protective and non-protective VT groups 
3.5.1 Patients characteristics  
Among the 57 patients ventilated in VAC, 47 (82.5 %) were ventilated with set VT of 
less than 8 ml/kg PBW for more than 75 % of time (Protective VT group). The 10 
remaining patients were ventilated with set tidal volumes of more than 8ml/kg PBW 
for more than 25% of time (Non-protective VT group). In the protective VT group, 
median VT/kg PBW was 6.1 [5.7-6.7] ml/kg. In the non-protective VT group, median 
VT/kg PBW was 7.9 [6.5-8.7]. Difference in VT/kg was significant between both 
groups (p < 0.0001). 
General patients’ characteristics in the protective and non-protective VT groups are 
given in Table 8. 
 
General data 
Protective VT 
N = 47 
Non-Protective VT 
N = 10 
P value 
Age [y] 50 [33-59] 35 [24-61] ns 
Height [cm] 170 [163-175] 155 [151-160] <0.0001 
Weight [kg] 60 [52-75] 55 [49-64] ns 
Predicted body 
weight  
65.9 [55.1-70.5] 47.8 [44.7-52.8] <0.0001 
Men/Women 27/20 1/9 0.0119 
On emergency list 6/47 (12,8%) 1/10 (10%) Ns  
Table 8 : Patients characteristics according to subgroups of tidal 
volumes. Vt = tidal volume  
 
    
 
  
16 
 
3.5.2 Gravity score 
SAPS II score was in median 32 [27-38] for the protective VT group and 34 [24.5-
39.5] for the non-protective VT group (p >0.05). SOFA and PGD scores for the 
protective and non-protective VT groups are given in Table 9. 
Score 
Protective VT 
N = 47 
Non-Protective VT 
N = 10 
ANOVAs 
SOFA day 1 7 [6-9] 7 [4-7.7] Ns 
SOFA day 3 5.5 [3.2-8.7] 1.5 [1-11.7] Ns 
PGD 0-1 day 1 25/47 5/10 Ns 
PGD 0-1 day 3 20/47 6/10 Ns 
PGD > 1 day 1 22/47 5/10 Ns 
PGD > 1 day 3 27/47 4/10 Ns 
Table 9: SOFA and PGD scores according to subgroups of tidal volume. Vt 
= tidal volume SOFA = sequential organ failure assessment PGD = primary 
graft dysfunction 
 
3.5.3 General outcome 
General outcome data for the protective and non-protective VT groups are given in 
Table 10.  
Outcomes 
Protective VT 
N = 47 
Non-Protective VT 
N = 10 
P value 
Stay in ICU (days) 4.8 [2.9-9.9] 5 [5.4-19.7] Ns 
Total stay in 
hospital (days) 
18.7 [15.9-30] 20.7 [12.7-37.8] Ns 
Table 10 : Outcomes according to the protective and non-protective 
VT groups. Vt = tidal volume 
 
3.5.5 Ventilation duration and information related to weaning from 
mechanical ventilation  
Detailed ventilation duration for the protective and non-protective VT groups are 
given in Table 11 
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Ventilation outcome 
Protective VT 
N = 47 
Non-Protective VT 
N = 10 
P values 
Duration of MV (days) 1 [0.5-3.9] 0.9 [0.5-6] Ns 
MV more than 48h 19/47 2/10 Ns 
MV more than 7 days 8/47 2/10 Ns 
Reintubation 4/47 1/10 Ns 
Table 11 : ventilation outcomes for the protective and non-protective VT 
groups. Vt = tidal volume MV = mechanical ventilation  
 
Figure 6 represents the total number of patients under invasive mechanical 
ventilation over time according to the groups of tidal volume (protective or non-
protective VT groups).  
 
 
 
Six patients (12.8%) from the protective VT group had to be tracheotomised. For the 
other group, 3 patients (30%) required tracheotomy (p >0.05). 
Concerning weaning from mechanical ventilation, the total PSV duration given as 6-
hour periods under PSV was in median 4 [1.5-50] for the protective VT group and 2 
[1-55] for the non-protective VT group (p >0.05).  
For the protective VT group, NIV was used in 29/47 patients (62%). For the non-
protective VT group, it was used in 8/10 patients (80%) (p >0.05). 
3.6 Patients characteristics and outcomes according to the predefined 
protective and non-protective driving pressure (DP) groups 
Among the 57 patients ventilated in VAC, 34 (59.6 %) were ventilated with DP of less 
than 15 cmH2O for more than 75 % of time (Protective DP group). The 23 remaining 
patients were ventilated with DP of more than 15 cmH2O for more than 25% of time 
(Non-protective DP group). In the protective DP group, median DP was 13 [11-15], 
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Figure 6 : Number of patients under mechanical ventilation over time. A) for the protective VT group B) for the 
non-protective VT group.  
MV= mechanical ventilation VT= tidal volume Tx = transplantation 
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whereas non protective DP group has in median a DP value of 17 [15-20] 
(p<0.0001). 
3.6.1 Patients characteristics  
General patients’ characteristics in the protective and non-protective DP groups are 
given in Table 12. 
General data Protective DP  Non protective DP P value 
Age [y] 54 [29-60] 48 [33-59] Ns 
Height [cm] 170 [158-175] 166 [158-173] Ns 
Weight [kg] 58 [51-70] 66 [52-78] Ns 
Predicted body 
weight  
64 [51-70] 60 [50-69] Ns 
Men 19 10 
Ns  
Women 15 13 
On emergency list 6/47 1/10 Ns  
Table 12 : ventilation outcomes according to subgroups of driving 
pressure. DP = driving pressure y = years cm =centimeters kg =kilogram  
 
3.6.2 Gravity score 
SAPS II score was in median 30 [26-35] for the protective DP group and 37 [29-46] 
for the non-protective DP group (p =0.0039).SOFA score at day 1 is displayed in 
figure 7.  
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Figure 7 : SOFA score at day 1 post lung transplant was in median 7 [6-7] in 
DP < 15 group and 9 [7-10] in DP > 15 group, with a p-value of 0.0032. 
DP = driving pressure Tx = transplantation SOFA = sequential organ failure 
assessment 
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SOFA score at day 3 was 3.5 [1.7-5.5] in the protective DP group and 8 [3-13.5] in 
the non-protective DP group (p>0.05). PGD scores for both groups are given in table 
13. 
 
 PGD Score 
Protective 
DP 
Non protective DP P value 
PGD 0-1 day 1 21 (61.8%) 9 (39.1%) 
Ns 
PGD 2-3 day 1 13 (38.2%) 14 (60.9%) 
PGD 0-1 day 3 25 (73.5%) 9 (39.1%) 
0.0136 
PGD 2-3 day 3 9 (26.5%) 14 (60.9%) 
Table 13 : PGD scores according to subgroups of driving pressure. DP 
= driving pressure PGD = primary graft dysfunction 
 
3.6.3 General outcome 
Stay duration in the ICU in days was in median 4.2 [2.8-6.5] days for the protective 
DP group, and 13.6 [4.2-32.8] days for the non-protective DP group (p =0.0005), as 
shown in figure 8. 
 
 
 
Total stay in hospital was 18.8 [16.3-23] days in the protective DP group whereas it 
was 29.4 [11.9-49] days in the non-protective DP group (p>0.05). 
The two patients who died during the hospital stay belong to the non-protective DP 
group. 
 
3.6.4 Ventilation duration and information related to weaning from 
mechanical ventilation  
0 20 40 60 80
Protective DP
Non Protective DP
Stay in ICU [days]
Days
G
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u
p
*
Figure 8 : duration of  stay in ICU after lung transplantation, according to the 
groups of DP  
DP = driving pressure. ICU = intensive care unit 
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Protective DP group had a median duration of mechanical ventilation of 0.7 [0.5-1.5] 
days. In non-protective DP group, median duration of MV was 4 [0.7-24] days (p-
value 0.0002). This is illustrated in figure 9. 
 
 
 
 
Figure 10 shows the number of patients under mechanical ventilation over time 
according to the protective and non-protective DP groups 
 
 
 
Patients from the non-protective DP group were more likely to be ventilated more 
than 48h (OR 7 [2-23], p = 0.001) and more than 7 days (OR 25 [3-282], p = 0.0002) 
than patients from the protective DP group, as shown in figure 11.  
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Figure 10: mechanical ventilation over time for a) protective DP group and b) non protective DP  
DP = driving pressure 
Figure 9 : Duration of mechanical ventilation according 
to the protective and non-protective DP. DP = driving 
pressure 
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Reintubation occurred in 2 of 34 patients (5.9%) in the protective DP group, and in 
3/23 (13.0%) in the non-protective DP group (p>0.05). Two patients of 34 (5.9%) 
underwent tracheotomy in the DP group, and 8/23 (34.8%) in the non-protective DP 
group (p=0.0105). 
 
4. Discussion 
 
We have analysed 60 patients who were lung transplanted in the Lausanne 
University hospital during the 16.07.2014 to 31.10.2017 period. Among these 
patients, the main reason for transplantation was cystic fibrosis (16/60 patients; 27%) 
followed by COPD (15/60 patients; 25%), Interstitial lung disease (ILD) (15/60 
patient; 25%) and others included patients (14/60; 23). These findings are similar to 
the latest statistics of adult lung transplantation worldwide according to the ISHLT (7) 
Six patients were transplanted while on an emergency transplantation list. Four of 
them suffered from ILD. We can hypothesize that this is due to the fact that the 
natural history of ILD is often characterized by sudden and irreversible exacerbations 
leading to acute respiratory failure and need for mechanical ventilation. In addition, 
ILD patients often suffer from systemic disease (12,13). 
As expected, the baseline patients’ characteristics were not the same according to 
the reason for transplantation. The CF patients were younger than the other 
subgroups whereas the COPD patients were the oldest. Interestingly, height was not 
different but weight was higher in ILD patients compared to CF patients.  
The severity at admission expressed by the SAPS II score was similar for the 
different pathologies leading to transplantation. Oppositely, at day 1, the SOFA score 
was lower in CF patients compared to ILD and other disease patients. In the early 
post-operative period, ILD and other disease patients were thus more severely ill.   
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Figure 11 : duration of mechanical ventilation for more than 48h (a) or more than 7 days (b) according to the groups of driving 
pressure. DP = driving pressure. MV = mechanical ventilation 
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We could hypothesize that because ILD patients more often have a systemic 
disease, they could be more at risk of developing organ failure in the early post-
operative period. Interestingly, ILD and other disease patients had not higher PGD 
score at day 1 and 3 post graft compared to CF and COPD patients. 
As they were more severely ill at day 1 after transplantation, we could expect worse 
outcome in ILD and other disease patients. In line, even if it was not significant, ILD 
and other patients tended to stay longer in the ICU than the patients of the other 
groups. ILD patients however did not stay longer in the hospital. Interestingly, no 
COPD patients stayed in the ICU for a prolonged period of time. Oppositely 1 CF 
patient, 5 ILD patients and 3 other disease patients stayed in the ICU for a long 
period of time. As there seems to be a trend for a prolonged stay among the ILD and 
other disease group, we could hypothesize that if we had included a higher number 
of patients this difference could have become significant.  
Concerning the general patient’s outcome, it is interesting to underline that overall 
hospital mortality was very low. Only two patients died during their hospital stay. 
 
If we now consider the ventilatory support delivered to the transplanted patients, all 
the patients were ventilated through an endotracheal tube at ICU admission. The 
median duration of mechanical ventilation was very low (1.0 [0.6-3.6] day). This 
finding is concordant with a recent international survey concerning mechanical 
ventilation after lung transplantation (4).Median ventilation duration was 0.6 days in 
the CF and COPD groups. Duration of ventilation was much longer in the ILD and 
other disease groups. The mechanical ventilation duration was similar in these last 
two groups. Except one CF patients, all the patients who were ventilated more than 7 
days were ILD and other disease patients. This again underlines that these patients 
are the most severely ill. In line, the majority of patients who had to be 
tracheostomized were ILD and other disease patients. This may indicate that ILD and 
other disease patients were more prone to have a difficult mechanical ventilation 
weaning. 
 
Concerning mechanical ventilation settings, it is important to underline that the large 
majority of delivered tidal volumes were of less than 8 ml/kg PBW and thus is the 
recommended range (14). Our data showed that delivered tidal volumes indexed for 
PBW during VAC ventilation was higher in COPD patients. The first potential 
explanation for the use of higher tidal volumes in the post transplantation period in 
COPD patients is that previously hypercapnic patients keep abnormal respiratory 
drive regulation (15) responsible for persistent hypercapnia during several days after 
transplantation. To try to correct blood gas analyses the caregivers could tend to use 
higher tidal volumes. This could also however be explained by the fact that the 
caregivers are used to ventilate COPD patients with higher tidal volumes as they are 
supposed to have higher vital capacity and/or higher pulmonary compliance. Of 
course this is no more the case after lung transplantation but we could imagine that 
the caregivers do not systematically take this into account.  
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Interestingly, independently from the reason for transplantation, patients who 
received more often VT > 8ml/kg were smaller and had a higher body mass index. 
This suggests that small and overweighed patients are more at risk of receiving too 
high VT. The same was true for female patients who were much more prone to 
receive tidal volumes of more than 8ml/kg PBW (odds ratio of 12.15).  These two 
results are also demonstrated by a recent observational study (16). Practically, we 
should take particular attention to correctly set the tidal volumes when selecting the 
ventilator settings in these specific patients’ subgroups. To be sure to apply the 
correct VT, it is mandatory to obtain the patient’s height to be able to compute the 
PBW and to take this information into account to set the ventilator. Again, even if 
there were some patients who received VT of more than 8 Ml/kg PBW, overall the 
median delivered VT were in the recommended range in our patient population. 
When we considered the groups predefined as protective and non-protective VT 
groups, it is interesting to observe that very few patients were classified in the non 
protective VT group. We found no differences in outcomes (ventilation duration, ICU 
and hospital stay duration) between the protective and non-protective VT groups. 
This could however be explained by the fact that no patients received very high tidal 
volumes in our population. 
 
Set PEEP values were relatively low, probably because the majority of the patients 
were not severely hypoxemic in the postoperative period. PEEP settings used are 
thus overall in line with the recommendations (17) and extreme PEEP values were 
never prescribed (range between 3 and 15 cmH2O). Interestingly, set PEEP was 
lower in COPD patients compared to CF and ILD patients. 
 
As already mentioned, VT and PEEP were overall prescribed according to the 
recommendations. Oppositely, the DP applied in our patients were often higher than 
the 15 cmH20 threshold now often considered as the safety limit (18). High DP may 
be deleterious to the patients, in terms of morbidity and mortality (19,20). Indeed, 
23/57 (40%) patients ventilated in VAC had DP above 15 cmH20 during more than 
75% of time (non-protective DP group). The patient’s characteristics were the same 
in the non-protective and protective DP groups suggesting that receiving DP above 
15 cmH20 was related to other factors. Interestingly, ILD and other disease patients 
had much more often DP of more than 15 cmH20 compared to CF and COPD 
patients. In other words, ILD and other disease patients were much more likely to be 
classified in the non-protective DP group with an OR of 3.92 (p = 0.0176). It is difficult 
to know why ILD and other disease patients were ventilated with higher DP than CF 
and COPD patients. However, a higher DP is an expression of reduced respiratory 
system compliance and we could hypothesize that as these patients had a higher 
BMI, they could have be more prone to develop lung atelectasis and that delivering 
higher PEEP could have been efficient to recruit, increase compliance and decrease 
driving pressure. In other words, we could imagine that using higher PEEP settings in 
these patients could have been better. 
Patients classified in the non-protective DP group had a higher PGD score at day 3. 
In line, they were ventilated for a longer period of time and stayed longer in the ICU 
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compared to the patients from the protective DP group. They were also more often 
ventilated for more than 48h and for more than 7 days In addition, they were more 
likely to require tracheotomy, showing that difficult weaning of mechanical ventilation 
was more likely to occur in these patients.  
To interpret these findings, it is however important to note that the patients classified 
in the non-protective DP group were more severely ill in the early post-operative 
period compared to the patients from the protective DP group as they had a higher 
SAPS II score and a higher SOFA score at day 1. Thus it is impossible based on the 
present results to determine whether the use of non-protective DP is the 
consequence or the cause of increased disease severity. To test the relationship 
between higher PGD score at day 3, longer mechanical ventilation duration, longer 
ICU stay duration and higher DP, it is mandatory to correct for the baseline post 
transplantation severity. This is planned as additional analysis but was not performed 
up to now. If a direct relationship was found between higher DP and worse outcomes 
this would be a strong rational to closely monitor DP and to adapt the ventilator 
settings (PEEP in particular) in order to keep DP values in a safe range, even if the 
existence of a DP safe range is still a matter of debate. 
 
Several limitations of this study must be underlined. First, only 60 patients were 
included in the analysis. Second, data were collected retrospectively. Very complete 
data automatically recorded in the clinician information system were however 
available for the analysis. Third, DP was computed based on a dynamic 
measurement of plateau pressure which could sometimes be overestimated. 
Similarly, no expiratory pause was performed to compute total PEEP, which could 
also be responsible for an approximation of DP. Fourth, we only considered 
mechanical ventilation applied in the post-operative period even if it seems probable 
that mechanical ventilation both delivered to the donor and used in the operating 
room could have some influence. Fifth, we did not take into account the transplanted 
lung size which could be a better determinant to compute the safest tidal volume to 
deliver in the post-transplant period. Finally as some patients were transferred to 
other hospital, the total duration of hospital stay could be underestimated. As only 
one patient was transferred to another ICU, ICU stay duration was not influenced by 
transfers. 
 
5. Conclusion 
Our retrospective study showed that in the Lausanne adult ICU, lung transplant 
patients were overall ventilated only during a short period of time. During the period 
of controlled ventilation, volume assist control was the preferred mode. Set tidal 
volumes were in the large majority of cases within the recommended range. PEEP 
was set to low values but overall in accordance to patients’ severity. Oppositely, DP 
applied was often higher than usually recommended. There was no relationship 
between delivered VT and ventilator or general outcomes but very few large VT were 
used in our patient’s population. Patients ventilated with higher DP were ventilated 
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for a longer period of time and stayed longer in the ICU, suggesting a potential 
deleterious effect of high DP. Patients who received high DP were however more 
severely ill in the early post-operative period. To be able to definitely conclude to a 
potential deleterious effect of high DP, further analyses to correct for the effect of 
disease severity in the post-operative period must be performed. 
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